This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Hagens Berman: 21 Days Remain Until May 13, 2014 Lead Plaintiff Deadline In CytRx Securities Fraud Class Action

Berkeley, Calif., April 23, 2014 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP reminds investors of the securities fraud class action against CytRx Corporation (NASDAQ: CYTR) ("CytRx" or "the Company") and the May 13, 2014 deadline to file for lead plaintiff. Investors who have suffered financial losses can contact Hagens Berman Partner Reed Kathrein, who is leading the firm's investigation, by emailing CytRx@hbsslaw.com, calling 510-725-3000 or visiting http://hb-securities.com/investigations/CytRx.

The securities fraud class-action lawsuit filed against CytRx on March 14, 2014 is on behalf of all persons who purchased or otherwise acquired CytRx stock between Nov. 20, 2013 and March 13, 2014 (the "Class Period"). The lawsuit also covers those who purchased CytRx stock in the offering completed February 5, 2014, in which CytRx netted more than $80 million.

The complaint, filed in the U.S. District Court for the Central District of California, alleges that the defendant violated federal securities laws when it employed The DreamTeam Group to write misleading articles under aliases without disclosing payment for the articles or any affiliation with the company. The complaint alleges that following the dissemination of CytRx's alleged false stock-promoting statements, the company's stock reached a high of $8.35 per share on Jan. 30, 2014.

On Feb. 5 2014, CytRx completed the sale of more than 11 million shares at $6.50 per share, acquiring more than $80 million in net proceeds, according to the complaint.

On Feb. 12, 2014, a senior columnist at TheStreet.com published an article, titled "Galena Biopharma Pays For Stock-Touting Campaign While Insiders Cash Out Millions," claiming an affiliated biotechnology company was engaging in a misleading campaign to boost the company's stock price. Following its publication, CytRx's alleged stock-touting practices and employment of the same firm – DreamTeam – were unveiled. Following this news, CytRx's stock price fell from $6.60 to a close of $6.04, declining in value 8.5 percent and damaging investors, according to the complaint.

On March 13, 2014, an additional published report alleged that CytRx shares quadrupled during a promotion via DreamTeam and that company management edited and approved the paid articles, according to the complaint. Following publication of the article, CytRx stock fell from $4.78 per share to a close of $4.17 per share on March 13, 2014. CytRx's stock continues to trade below previous figures, closing at $3.00 on April 16, 2014.

"Past examples have shown that when companies risk their stock values on false information, it never ends well for stakeholders or the company," said Mr. Kathrein. "In light of these allegations, Hagens Berman is continuing its deep-reaching investigation against CytRx."

The deadline to file for lead plaintiff in the securities fraud class action is May 13, 2014.

Persons with non-public information regarding CytRx should consider their options to help in the investigation or take advantage of the SEC Whistleblower program. Under the new SEC Whistleblower program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information call Reed Kathrein at 510-725-3000 or email one of the links above.

About Hagens Berman

Hagens Berman Sobol Shapiro LLP is an investor-rights class-action law firm with offices in nine cities. The Firm represents investors, whistleblowers, workers and consumers in complex litigation. More about the law firm and its successes can be found at www.hb-securities.com. Read the firm's Securities Newsletter at http://www.hb-securities.com/newsletter. The firm's blog is located at www.meaningfuldisclosure.com.

ContactsFirmani + Associates Mark Firmani, 206-443-9357 mark@firmani.com

SOURCE Hagens Berman Sobol Shapiro LLP

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs